Drug intelligence / Profile preview

siMT-2A_2

Development stage: Preclinical
Lead developer: National University of Singapore
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

siMT-2A_2 is a chemically synthesized small interfering RNA (siRNA) duplex designed to target and silence the expression of the metallothionein-2A (MT-2A) isoform. Developed by researchers at the National University of Singapore, it has been studied in preclinical breast cancer models (such as MCF-7 cells) to evaluate the effects of MT-2A knockdown on cell viability, chemotherapy sensitivity (e.g., to doxorubicin), and downstream gene expression, particularly interferon-inducible pathways.

Targets

MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on siMT-2A_2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on siMT-2A_2.

Explore the full profile